October 13, 2021 News by Marisa Wexler, MS #ECTRIMS2021 ā Ponvory Effective in Early MS in OPTIMUM Trial Editorās note: TheĀ Multiple Sclerosis News Today team is providing in-depth coverage of the virtual 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Oct. 13ā15. GoĀ hereĀ to see the latest stories from the conference.
October 11, 2021 News by Patricia Inacio, PhD NICE Opposes Ponvory Being Added to NHS for England and Wales The National Institute for Health and Care Excellence (NICE) will not recommend that Ponvory (ponesimod) be added to the National Health Service (NHS) of England and Wales for people with active, relapsing forms of multiple sclerosis (MS). The provisional decision, made because Ponvory was not found to be…
June 21, 2021 News by Marisa Wexler, MS Results: Ponvory Outperforms Aubagio in OPTIMUM Clinical Trial In the OPTIMUM clinical trial,Ā Ponvory (ponesimod) significantly outperformed Aubagio (teriflunomide) in reducing relapse rates, fatigue, and evidence of brain damage among people with relapsing multiple sclerosis (MS). Based on these results, Ponvory has now been approved in the U.S. and the European Union as a treatment…
September 10, 2020 News by Marta Figueiredo, PhD #MSVirtual2020 – Ponesimod Superior to Aubagio in Delaying Disability Progression in Relapsing MS, Trial Data Show Janssen Pharmaceuticalsā investigational oral therapy ponesimod is superior to Sanofiās Aubagio (teriflunomide) in delaying disability progression in adults with relapsing multiple sclerosis (MS), according to exploratory analyses of OPTIMUM clinical trial data. These and other findings from Janssenās MS research program, including on the health…
March 20, 2020 News by Marisa Wexler, MS Janssen Seeks FDA Approval for Oral Ponesimod for Treating Relapsing MS Janssen has submitted an application to the U.S. Food and Drug Administration (FDA) asking for ponesimodĀ to be approved as an oral treatment for adults with relapsingĀ multiple sclerosis (MS). Ponesimod, formerly ACT-128800, is an experimental treatment that targets the proteinĀ sphingosine-1-phosphate…
March 12, 2020 News by Marisa Wexler, MS Ponesimod, Up for Approval, Shows ‘Clear Superiority’ Over Aubagio, Janssen Exec Says PonesimodĀ may soon be a new oral therapy for people with relapsing multiple sclerosis (MS) in Europe, and a filing for its approval in the U.S. is likely within weeks. Janssen Pharmaceuticals, its developer,Ā submitted an applicationĀ to the European Medicines Agency (EMA) inĀ early March, a first ponesimod filing…
March 5, 2020 News by Marisa Wexler, MS Janssen Asks EMA to Approve Oral Ponesimod to Treat Relapsing MS JanssenĀ has submitted an application toĀ the European Medicines Agency (EMA) asking that ponesimodĀ be approved as an oral treatment for adults with relapsing multiple sclerosis (MS) in the European Union. Ponesimod (formerly ACT-128800) is an experimental treatment that targets theĀ sphingosine-1-phosphate receptor…
September 18, 2019 News by Ana Pena PhD #ECTRIMS2019 ā Ponesimod Superior to Aubagio in Relapsing MS, OPTIMUM Trial Shows Actelion‘s ponesimod, an investigational oral treatment, is superior to Sanofi‘s Aubagio (teriflunomide) in lessening the frequency of relapses and easing fatigue symptoms in adults with active, relapsing multiple sclerosis (MS), results of the OPTIMUM trial show. These data will lay the ground for submissions…
July 30, 2019 News by Ana Pena PhD Ponesimod Fares Well in Phase 3 Trial for Relapsing MS, Janssen Announces JanssenĀ has announced positive, top-line results from its Phase 3 OPTIMUM study, testing the effectiveness and safety of ponesimod tablets, compared to Sanofi‘s Aubagio (teriflunomide), in adults with relapsing forms of multiple sclerosis (MS). The study met its primary goal ā a reduction in the…